Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573017 | 0.89 | F10 (0.39) | ALDH1A1SMN1; SMN2MAPK1NPSR1AKR1C2 | |
| SCHEMBL1573171 | 0.88 | NR1H4 (0.42) | ALDH1A1NPSR1AKR1C2AKR1C1MEN1 | |
| SCHEMBL4522091 | 0.88 | RAB9A (0.39) | LMNARAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13918726 | 0.88 | F10 (0.38) | LMNAALDH1A1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL1573416 | 0.88 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2NPSR1AKR1C2AKR1C1 | |
| SCHEMBL4518702 | 0.88 | MEN1 (0.38) | ALDH1A1SMN1; SMN2NPSR1AKR1C2AKR1C1 | |
| SCHEMBL1573349 | 0.87 | ALDH1A1 (0.37) | ALDH1A1KAT6ANPSR1AKR1C2AKR1C1 | |
| SCHEMBL1572822 | 0.87 | F10 (0.38) | LMNAALDH1A1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL1573409 | 0.84 | ALDH1A1 (0.43) | LMNAALDH1A1SMN1; SMN2MAPK1NPSR1 | |
| SCHEMBL150004 | 0.84 | MAPT (0.46) | LMNARAB9AALDH1A1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | LMNA 3360/4885RAB9A 1820/4885ALDH1A1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.